Non-Invasive Test Detects Up To 42 Solid Tumors and Five Blood Cancers in Blood and Urine Samples

Cancer is now responsible for nearly 1 in 6 deaths worldwide. Each year, over 14 million people are diagnosed with cancer, and this number is expected to surpass 21 million by 2030. A major issue is that many cancer cases are detected too late. Approximately 70% of all cancer-related deaths stem from cancers for which there are no established screening tests, and these are often diagnosed at an advanced stage, making treatment more difficult. Even in countries with highly developed healthcare systems, a significant number of cancers are identified at a late stage, when successful treatment is more challenging. There is a pressing need for innovative, non-invasive screening tests to detect cancer in asymptomatic individuals, particularly during the early stages when treatment is most effective. A new Multi-Cancer Early Detection (MCED) test, using routine blood and urine samples and powered by a machine learning (ML) algorithm, now offers the potential to screen for up to 42 solid tumors and five hematological tumors.

Developed by Kience Inc. (Wilmington, DE, USA), the Venient Sx MCED test can accurately detect 42 types of solid tumors and 5 hematological tumors, which together represent 95.2% of all new cancer cases globally. It is capable of identifying cancer at early stages, even before symptoms appear, allowing for more successful treatment. Additionally, the test screens for up to 276 non-malignant diseases related to major bodily functions, systems, and overall metabolism, many of which are known risk factors for cancer.

Image: The MCED test can screen for up to 42 solid tumors and five hematological tumors (Photo courtesy of 123RF)

The Venient Sx MCED test provides insights into the potential onset of diseases years in advance by analyzing clinical data, lab results, and lifestyle factors. The comprehensive, personalized report generated by the test suggests preventive measures to address both non-malignant diseases and potential cancer risks, helping to prevent their natural progression. Studies validating the Venient Sx MCED test have shown it achieves 95% sensitivity, 73% specificity, and 95% accuracy across 276 non-malignant conditions. Venient Sx MCED test has already obtained CE Mark and is currently under US certification.

Related Links:
Kience Inc.